medigraphic.com

2019, Number 2

<< Back Next >>

Rev Clin Esc Med 2019; 9 (2)

Generalidades del cáncer gástrico

Rojas-Montoya V, Montagné N

Language: Spanish
References: 14
Page: 22-29
PDF size: 471.01 Kb.


ABSTRACT

Gastric cancer has an important social impact because it is one of the leading causes of cancer death. Only 1-3 % of cases have a hereditary component, which suggests an environmental origin. Gastric cancer tends to emerge from gastritis or underlying chronic inflammation accompanied by hypochlorida, which is usually caused by Helicobacter pylori. When faced with a harmful stimulus, the normal epithelium of the stomach develops chronic atrophic gastritis that progresses to metaplasia and subsequently to dysplastic lesions. The symptomatology is usually very nonspecific and initially the physical examination is normal. The diagnosis is then delayed and is performed by means of endoscopy plus biopsy. Routine screening with gastroscopy is not recommended even if the epidemiological data of gastric cancer remains alarming.


REFERENCES

  1. 1- Abbas M Faggian A Sintali DN et al. Current and future biomarkers in gastric cancer. Biomedicine & Pharmacotherapy. 2018; (103): NO 1688-1700. doi:10.1016/j.biopha.2018.04.178

  2. 2- Amieva M Peek RM. Pathobiology of Helicobacter pylori–Induced Gastric Cancer. Gastroenterology. 2016; (150): NO 64-78. doi:10.1053/j.gastro.2015.09.004

  3. 3- Correa P. Gastric Cancer. Gastroenterology Clinics of North America. 2013; (42): NO 211-7. doi:10.1016/j.gtc.2013.01.002

  4. 4- Cruz Brenes A. Generalidades del Cáncer Gástrico. Revista Médica De Costa Rica Y Centroamérica. 2013. NO 263-8.

  5. 5- Cutsem EV Sagaert X Topal B Haustermans K Prenen H. Gastric cancer. The Lancet. 2016; (388): NO 2654-64. doi:10.1016/s0140-6736(16)30354-3

  6. 6- Hartgrink H Jansen E Grieken NV Velde CV. Gastric cancer – Authors reply. The Lancet. 2009; (374): NO 1594-5. doi:10.1016/s0140-6736(09)61948-6

  7. 7- Lamarca Lete A Molina Villaverde R Navarro Expósito F Álvarez Mon Soto M. Cáncer de estómago. Centro Nacional De Biotecnología. 2013. NO 1512-8.

  8. 8- Mamon H Enzinger PC. Adjuvant and neoadjuvant treatment of gastric cancer. UpToDate. 2018.

  9. 9- Moss SF. The Clinical Evidence Linking Helicobacter pylori to Gastric Cancer. Cellular and Molecular Gastroenterology and Hepatology. 2017; (3): NO 183-91. doi:10.1016/j.jcmgh.2016.12.001

  10. 10- Obermannová R Lordick F. Management of Metastatic Gastric Cancer. Hematology/Oncology Clinics of North America. 2017; (31): 469-83. doi:10.1016/j.hoc.2017.01.006

  11. 11- Sierra R. Cáncer gástrico, epidemiología y prevención. Acta Médica Costarricense. 2002. NO: 55-61.

  12. 12- Suzuki H Iwasaki E Hibi T. (2009). Helicobacter pylori and gastric cancer. Gastric Cancer. 2009. (12): NO 79-87. doi:10.1007/s10120-009-0507-x

  13. 13- Villalobos González MA. Cáncer gástrico: (Revisión Bibliográfica). Revista Médica de Costa Rica y Centroamérica. 2008. NO 99-101.

  14. 14- Yakirevich E Resnick MB. Pathology of Gastric Cancer and Its Precursor Lesions. Gastroenterology Clinics of North America. 2013; (42): NO 261-84. doi:10.1016/j.gtc.2013.01.004




2020     |     www.medigraphic.com